Site Editors

Shaji K. Kumar, MD

Prashant Kapoor, MD, FACP


BCMA-Targeting CAR T-Cell Product for Relapsed or Refractory Multiple Myeloma

By: Julia Fiederlein
Posted: Tuesday, July 12, 2022

According to Carlos Fernandez De Larrea, MD, PhD, of the University of Barcelona, and colleagues, the lentiviral autologous chimeric antigen receptor (CAR) T-cell product ARI0002h seems to be safe and active in patients with relapsed or refractory multiple myeloma. The results of the multicenter CARTBCMA-HCB-01 trial, which were presented during the European Hematology Association (EHA) 2022 Congress (Abstract S103), highlighted the absence of neurotoxicity and the feasibility of a second booster dose.

A total of 35 patients were enrolled and allowed bridging therapy between apheresis and lymphodepletion with cyclophosphamide plus fludarabine. Of this population, 30 were administered 3 x 106/kg CAR-positive cells in a fractionated manner. Patients who achieved any response and had not experienced serious complications were eligible to receive a second dose after at least 4 months.

The overall response rate was 100%, with a stringent complete remission plus a very good partial response rate of 90%. The median time to first response was 1 month. Of the 26 patients who were evaluable for measurable residual disease (MRD) after 100 days, 92% achieved MRD negativity in the bone marrow. A total of 53% of patients were alive and without disease progression at 16 months. The median duration of overall survival was not reached, and the 16-month overall survival rate was 80%.

Cytokine-release syndrome (87%), neutropenia (97%), anemia (85%), and thrombocytopenia (79%) were the most frequently reported adverse events. No cases of CAR T-cell–related neurotoxicity were reported. A total of 76% and 12% of patients were administered tocilizumab and corticosteroids, respectively. ARI0002h cells exhibited peak expansion on day 14.

Most eligible patients (86%) received a second dose. The median duration of time after the first infusion was 4 months, and 38% of patients received a second lymphodepletion regimen. After the second infusions, no relevant toxicities were reported. A total of 29% of patients had an improved response after reinfusion.

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.